Avid Bioservices Inc (CDMO)

[tech0200]

I wonder how much bigger is the reach of this article compared to MD's article to date.

What do those on this board who have blamed Peregrine for botching the phase II trial say to this? Do they have more credibility than The Motley Fool?

"In midstage studies, bavituximab led to a statistically significant improvement in media overall survival to 11.7 months from 7.3 months. Of course, this was after some controversy with a third-party laboratory that botched the results and made Peregrine retract its initial top-line figures. Bavituximab is currently being studied in a late-stage study known as SUNRISE, with results expected in December 2016."

http://www.fool.com/investing/general/2015/06/13/1-drug-will-make-or-break-these-3-biotech-stocks.aspx